These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 16489096)

  • 1. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
    Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
    Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.
    Pollack VA; Alvarez E; Tse KF; Torgov MY; Xie S; Shenoy SG; MacDougall JR; Arrol S; Zhong H; Gerwien RW; Hahne WF; Senter PD; Jeffers ME; Lichenstein HS; LaRochelle WJ
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):423-35. PubMed ID: 17541593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
    Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
    Naumovski L; Junutula JR
    Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate.
    Qian X; Mills E; Torgov M; LaRochelle WJ; Jeffers M
    Mol Oncol; 2008 Jun; 2(1):81-93. PubMed ID: 19383330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
    Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
    Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma.
    Asundi J; Reed C; Arca J; McCutcheon K; Ferrando R; Clark S; Luis E; Tien J; Firestein R; Polakis P
    Clin Cancer Res; 2011 Mar; 17(5):965-75. PubMed ID: 21245091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
    Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
    Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma.
    Mills L; Tellez C; Huang S; Baker C; McCarty M; Green L; Gudas JM; Feng X; Bar-Eli M
    Cancer Res; 2002 Sep; 62(17):5106-14. PubMed ID: 12208768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPNMB expression in uveal melanoma: a potential for targeted therapy.
    Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
    Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis.
    Saleem M; Maddodi N; Abu Zaid M; Khan N; bin Hafeez B; Asim M; Suh Y; Yun JM; Setaluri V; Mukhtar H
    Clin Cancer Res; 2008 Apr; 14(7):2119-27. PubMed ID: 18381953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
    Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Shochat D; Mountain A
    Bioconjug Chem; 2005; 16(2):354-60. PubMed ID: 15769089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress.
    Baldi A; Lombardi D; Russo P; Palescandolo E; De Luca A; Santini D; Baldi F; Rossiello L; Dell'Anna ML; Mastrofrancesco A; Maresca V; Flori E; Natali PG; Picardo M; Paggi MG
    Clin Cancer Res; 2005 May; 11(9):3175-83. PubMed ID: 15867210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
    Hamblett KJ; Senter PD; Chace DF; Sun MM; Lenox J; Cerveny CG; Kissler KM; Bernhardt SX; Kopcha AK; Zabinski RF; Meyer DL; Francisco JA
    Clin Cancer Res; 2004 Oct; 10(20):7063-70. PubMed ID: 15501986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
    Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R
    Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mHFE7A, a newly identified monoclonal antibody to Fas, induces apoptosis in human melanoma cells in vitro and delays the growth of melanoma xenotransplants.
    Hiramoto K; Inui M; Kamei T; Okumura K; Nakase M; Tagawa T
    Oncol Rep; 2006 Feb; 15(2):409-15. PubMed ID: 16391862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gammaCnull (NOG) mouse model.
    Ikoma N; Yamazaki H; Abe Y; Oida Y; Ohnishi Y; Suemizu H; Matsumoto H; Matsuyama T; Ohta Y; Ozawa A; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Sep; 14(3):633-7. PubMed ID: 16077966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.